{"id":"W2805341297","doi":"10.1016/s1470-2045(18)30354-1","title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Amgen","keywords":"Carfilzomib; Medicine; Dosing; Refractory (planetary science); Interim analysis; Interim; Multiple myeloma; Lenalidomide; Internal medicine; Oncology; Clinical trial; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001091498,0.0002289043,0.001142556,0.0003226452,0.0001134954,0.00001540598,0.0002149422,0.0001049525,0.00003189745],"category_scores_gemma":[0.001018537,0.0001395118,0.00008446286,0.0007199424,0.0004500679,0.00009747558,0.0001322086,0.0003540453,0.000009249703],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002881306,"about_ca_system_score_gemma":0.0001663423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001323357,"about_ca_topic_score_gemma":0.003763986,"domain_scores_codex":[0.9973913,0.0007033726,0.0005615875,0.0004746694,0.0003899276,0.0004791212],"domain_scores_gemma":[0.9973038,0.001229546,0.000341312,0.000698348,0.0002672928,0.0001596783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6216363,0.003779256,0.3508776,0.00003156116,0.002097876,0.0001396585,0.004238474,0.000003756751,0.000959187,0.000002810458,0.000222424,0.01601115],"study_design_scores_gemma":[0.4303021,0.02573388,0.5401656,0.00006088522,0.000820399,0.000003337367,0.001166891,0.0005168282,0.0003062318,0.000002447859,0.0008066337,0.0001147282],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957838,0.00008117568,0.00002370567,0.0005790176,0.0001174252,0.001691401,0.00007694151,0.00002960743,0.001616906],"genre_scores_gemma":[0.9987162,0.00003082718,0.0006907875,0.00008395552,0.0001635128,0.00008767789,0.00007943975,0.00002143892,0.00012613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1913341,"threshold_uncertainty_score":0.5689127,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05709115066878615,"score_gpt":0.3817391800709356,"score_spread":0.3246480294021494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}